Category: Neurological
Neurological
New York Times' article on Alzheimer's disease study chastised by medical journalism critics for ignoring statistical flaws in research.
By Merrill Goozner
HealthNewsReview.org gave Gina Kolata's front-page New York Times story touting spinal taps to predict Alzheimer's disease a two-star rating — out of five. Chief complaint: its 100 accuracy claim ignored the test's "specificity" problem. Over a third of people told they were on the road to dementia didn't develop the disease.
I'm glad somebody blew the whistle on this latest example of hyped health care coverage that so consistently emanates from the word processor of Ms. Kolata.
NeuroMetrix Inc.'s second-quarter sales plunged 43 percent and its Q2 net losses more than doubled, forcing it to lay off 25 percent of its workforce, revamp its sales operation and table development of one of its pipeline products.
NeuroMetrix Inc. (NSDQ:NURO) took a pasting during the second quarter, as sales plunged 43.0 percent and net losses widened by 151.0 percent, forcing the nerve testing equipment maker to lay off 25 workers, reorganize its sales force and table the development of its Ascend anesthesia device.
The Waltham, Mass.-based firm reported net losses of $4.5 million, or 20 cents per share, on sales of $3.9 million during the three months ended June 30. That compares with net losses of $1.8 million, or 13 cents per share, on sales of $6.8 million during Q2 2009.
NeuroMetrix Inc. posted fourth-quarter profits of $363,000, due to a $2.2 million revaluation of warrants last year, but full-year 2009 profits still elude the nerve conduction test equipment maker.
A revaluation of warrants and a change in reimbursement policy helped produce fourth-quarter profits and hope for future top-line growth for NeuroMetrix Inc. (NSDQ:NURO).
Micrus Endovascular Corp. posted a profitable third quarter and a 24 percent increase in Q3 revenues.
Micrus Endovascular Corp. (NSDQ:MEND) posted third-quarter sales of $22.8 million for the three months ended Dec. 31, 2009, up 24.4 percent compared with $18.3 million during the same period in 2008. The company swung from a net loss of $2.3 million during Q3 2009 to net income of $3.3 million during Q3 2010:
Press Release
Micrus Endovascular Reports Fiscal Third Quarter Revenues of $22.8 Million and Diluted EPS of $0.20
Record Quarterly Revenues up 24%; Double-digit Revenue Growth in All Major Geographic Regions; Fourth Consecutive Quarter of Profitability
A judge in the U.S. District Court for Massachusetts dismissed a shareholders' lawsuit accusing NeuroMetrix Inc. of misleading investors about the prospects for reimbursement for its NC-Stat device.
A federal judge in Boston dismissed a lawsuit filed against NeuroMetrix Inc. (NSDQ:NURO) by shareholders accusing the company and its management of misleading them over reimbursement for its NC-Stat device.
Judge Rya Zobel of the U.S. District Court for Massachusetts ruled that the plaintiffs, the pension fund of the IBEW-NECA electrical workers' union, failed to establish that NeuroMetrix and its then-management team misled investors in quarterly regulatory filings and in conference calls with analysts discussing quarterly results.
A wireless brain-machine interface allows a patient with locked-in syndrome to speak vowels; "Bronchial GPS" lung navigation; a urine check for pneumonia; and an off-road wheelchair.
Wireless brain-computer link returns vowels to paralyzed man: Locked-In Syndrome, which leaves patients aware but almost entirely without the power to move, is one of the most terrifying potential results of brain lesions. Now, a collaboration of American researchers has implanted a wireless brain-machine interface, developed by Neural Signals of Duluth, Ga., into a locked-in subject who is almost completely paralyzed. The system uses brain electrodes to read signals meant for jaw and mouth muscles. An FM radio is used to transmit these brain signals to a computer, which transforms them into recognizable sounds.
